April 18th 2024
Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
ICER: Greater Transparency of Coverage Policies Needed
November 3rd 2023The Institute for Clinical and Economic Review’s fair access report found that for the drugs assessed, formularies provided fair access, but it was difficult to determine how well that translates into real-world access and affordability for patients.
Study Reveals Inconsistent Wait Times for Decisions on Cancer Drug Coverage
October 27th 2023The mean lag time between FDA approval and insurance coverage for 89 cancer drugs ranged from 2.3 months to 8.2 months. But cancer drugs approved more recently were more likely to have shorter coverage lags.